Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413092 | 0.83 | CYP1A2 (0.42) | ALDH1A1KMT2ALMNASMN1; SMN2SLC9A1 | |
| SCHEMBL4405814 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KMT2ALMNASOS1TSHR | |
| SCHEMBL4403852 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KMT2ALMNASOS1TSHR | |
| SCHEMBL22952515 | 0.80 | LMNA (0.38) | ALDH1A1KMT2ALMNA | |
| SCHEMBL4407082 | 0.80 | LMNA (0.33) | ALDH1A1KMT2ALMNA | |
| SCHEMBL4409069 | 0.79 | KMT2A (0.41) | ALDH1A1KMT2ALMNATSHRSLC9A1 | |
| SCHEMBL14420947 | 0.78 | ALDH1A1 (0.42) | ALDH1A1KMT2ALMNASOS1TSHR | |
| SCHEMBL4404184 | 0.78 | SLC9A1 (0.40) | KMT2ALMNASLC9A1MEN1CYP2C19 | |
| SCHEMBL4408134 | 0.77 | ALDH1A1 (0.41) | ALDH1A1KMT2ALMNASOS1TSHR | |
| SCHEMBL4405725 | 0.77 | CNR2 (0.43) | ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9873705-B2 | Vinylogous thioester compounds and methods of use | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873705-B2 | Vinylogous thioester compounds and methods of use | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-8394951-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-07-22 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ALDH1A1 3311/4885KMT2A 4528/4885LMNA 3801/4885 |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885LMNA 892/4885 |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | ACOT7, LYPLA2, PPT1 | ALDH1A1 1113/4885KMT2A 1205/4885LMNA 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.